THC:CBD Spray Improved MS Spasticity in Real-World Italian Clinics at Lower Doses Than Clinical Trials | Research

The takeaway

In a large Italian observational study, MS patients treated with THC:CBD spray in routine clinical practice achieved meaningful spasticity improvements at about one-third the dose used in clinical trials, with one-third the adverse event rate.

Read this if you have MS spasticity and are considering or already using Sativex.

Effective spasticity relief at ~1/3 the RCT dose with ~1/3 the adverse events in real-world practice.

What the researchers found

The MOVE 2 Italy study tracked real-world outcomes of THC:CBD oromucosal spray (Sativex) for treatment-resistant MS spasticity across more than 30 Italian MS centers. After surpassing 300 enrolled patients, an interim analysis compared results with the German MOVE 2 study and the largest phase III randomized controlled trial.

Patients showed meaningful improvements on both patient-reported and physician-rated spasticity scales over 3 months. Treatment discontinuations were limited, suggesting good tolerability.

Two key findings distinguished real-world from trial outcomes: patients achieved improvements at mean daily doses approximately one-third lower than those used in the pivotal RCT, and the proportion reporting adverse events was approximately one-third of the trial rate. THC:CBD spray was most commonly added to oral baclofen.

Why it matters

Real-world data often tells a different story than clinical trials. In this case, the story is more positive: patients achieved good results with lower doses and fewer side effects than expected from trial data. This suggests that the clinical trial setting may have led to higher dosing than necessary, and that in practice, lower doses are both effective and better tolerated.

The numbers in context

Over 300 patients enrolled across 30+ Italian MS centers. Meaningful improvements on NRS and modified Ashworth scale over 3 months. Mean daily doses approximately one-third of RCT doses. Adverse event rate approximately one-third of RCT rate. Limited treatment discontinuations.

How the study worked

Prospective observational study (MOVE 2 Italy) using web-based real-time data collection and patient diaries across more than 30 Italian MS centers. Outcomes included the patient-based 0-10 numerical rating scale for spasticity and physician-rated modified Ashworth scale. Interim analysis performed after 300 patient enrollment threshold.

What this study cannot tell us

Observational design without a control group means improvements could reflect placebo effects or natural disease fluctuation. Interim analysis rather than final results. Selection bias may be present if centers or patients with better outcomes were more likely to be captured. No randomization or blinding.

How to read the evidence

Moderate evidence from a large multi-center observational study providing valuable real-world effectiveness data, though limited by lack of control group.

When this study was published

Published in 2016. MOVE 2 Italy has continued to collect data since this interim analysis.

The bigger picture

This study bridges the gap between controlled trial evidence and clinical practice for cannabinoid-based MS treatment. The finding that lower doses work in practice suggests that the "start low, go slow" approach to cannabinoid dosing is not just safer but may be equally effective.

Questions still open

Why do lower doses work in clinical practice compared to trials? Is it because trial protocols mandate dose escalation? Does the addition of baclofen synergize with Sativex to allow lower cannabinoid dosing? What are the long-term outcomes beyond 3 months?

Common questions

Does Sativex work for MS spasticity in real patients?

Yes. This study of over 300 patients across 30+ Italian MS centers found meaningful spasticity improvements. Patients achieved these results at lower doses and with fewer side effects than seen in clinical trials.

How much Sativex do MS patients typically need?

In this real-world study, effective doses were about one-third of what was used in clinical trials. This suggests a "start low" approach may be sufficient for many patients, avoiding the higher doses and side effects associated with trial protocols.

Read the original research

THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.

European neurology, 75 Suppl 1, 4-8

View on PubMed ↗Publisher’s paper ↗

Citation

Trojano, Maria. (2016). THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.. European neurology, 75 Suppl 1, 4-8. https://doi.org/10.1159/000444235